tafamidis meglumine

Drug ingredient

CAS 951395-08-7

This chemical is an active pharmaceutical ingredient used in FDA-regulated drugs.

Molecular structure of 951395-08-7
US productionNot reported
Top sourceNo public record

This chemical is not on EPA’s Toxic Substances Control Act inventory, the list behind EPA’s production survey.

Why supply is unknown

Where It Comes From

EPA and Census publish no US supply data for this chemical.

13 FDA-registered drug labelers
Alivus Life Sciences Limited
Apothecon Pharmaceuticals Pvt Ltd
Aurobindo Pharma Limited
Biophore india pharmaceutical PVT Ltd
Catalent Pharma Solutions, LLC
DELMAR CHEMICALS INC
Honour Lab Limited
Inke SA
MSN Laboratories Private Limited
Neuland Laboratories Limited
NURAY CHEMICALS PRIVATE LIMITED
Pfizer Laboratories Div Pfizer Inc
TAPI Croatia Industries Ltd.

Why It Matters

Sectors
Health
Downstream Uses

Appears in 1 drug and cosmetic product listings (FDA).

  • •Vyndaqel
FDA Shortage Status
No Shortage
Shortage History
  • to be discontinued

    Tafamidis Meglumine Capsule

    Shortage listed since September 29, 2025

See all current drug shortages

Chemical Identity

CAS951395-08-7
PubChem CID24970412
DTXSIDDTXSID50915094
FormulaC21H24Cl2N2O8
Mol. Weight503.3 g/mol
SMILESCNCC(C(C(C(CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl

Data Sources

Brief citations

tafamidis meglumine (CAS 951395-08-7) https://chemicalindependence.com/chemical/951395-08-7/ PubChem: 24970412. Retrieved 2026-04-07. https://pubchem.ncbi.nlm.nih.gov/compound/24970412 FDA National Drug Code directory: CAS 951395-08-7. Retrieved 2026-04-25. https://open.fda.gov/data/ndc/ FDA Drug Shortages: CAS 951395-08-7. Retrieved 2026-10-04. https://www.accessdata.fda.gov/scripts/drugshortages/